Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Auditor change
|
|
Cellular Biomedicine Group, Inc. (CBMG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/03/2021 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 02/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/26/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/19/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/19/2021 |
SC 13D/A
| Liu Tony reports a 0% stake in Cellular Biomedicine Group, Inc. |
| 02/19/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/19/2021 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 02/19/2021 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...|
Docs:
|
"AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CELLULAR BIOMEDICINE GROUP, INC. ARTICLE ONE The name of the corporation is Cellular Biomedicine Group, Inc. . ARTICLE TWO The address of the Corporation’s registered office is at Suite 302, 4001 Kennett Pike, County of New Castle, Wilmington, DE 19807. The name of its registered agent at such address is Maples Fiduciary Services Inc. ARTICLE THREE The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware . ARTICLE FOUR The total number of shares which the Corporation shall have the authority to issue is one thousand , all of which shall be shares of common stock, with a par value of one cent per share, and are to be of one ...",
"ARTICLES OF INCORPORATION / BYLAWS",
"CELLULAR BIOMEDICINE GROUP, INC. ANNOUNCES COMPLETION OF MERGER ROCKVILLE, MD and SHANGHAI, China – Cellular Biomedicine Group, Inc. today announced the completion of the merger of the Company with CBMG Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands , pursuant to the previously announced Agreement and Plan of Merger , dated as of August 11, 2020, by and among the Company, Parent and Merger Sub. Under the terms of the Merger Agreement, which was approved by the Company’s stockholders at its special meeting of stockholders held on February 8, 2021, each share of the Company’s common stock, par value $0.001 per share , issued and outstanding immediately prior ..." |
|
| 02/08/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/01/2021 |
8-K
| Quarterly results |
| 01/28/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/26/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/25/2021 |
GN
| SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the Firm |
| 01/08/2021 |
GN
| MERGER INVESTIGATION: Halper Sadeh LLP Investigates CBMG, ALSK, UROV, NAV; Shareholders Are Encouraged to Contact the Firm |
| 12/29/2020 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 12/29/2020 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 12/28/2020 |
GN
| Rigrodsky & Long, P.A. Reminds Investors of Investigation of Cellular Biomedicine Group, Inc. Buyout |
| 12/12/2020 |
GN
| INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm – CBMG, MVC, STND, EIDX |
| 12/08/2020 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 12/08/2020 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 12/04/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/25/2020 |
GN
| Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – GLIBA, CBMG, MVC, PTI |
| 11/17/2020 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 11/17/2020 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 11/13/2020 |
GN
| SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Investigations; Investors are Encouraged to Contact the Firm – CBMG, MVC, PTI, CGIX |
| 11/06/2020 |
GN
| ALERT: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – GLIBA, CBMG, VRTU, MOBL |
| 11/03/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of BSTC, CBMG, CIT, and STND Buyouts |
| 10/26/2020 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"BRIDGE LOAN AGREEMENT This BRIDGE LOAN AGREEMENT is made and entered into on October 23, 2020 , by and among the following parties: 1. Cellular Biomedicine Group, Inc., a Delaware corporation ; 2. TF I Ltd. . The Company and the Lender are collectively referred to below as the “Parties” and each a “Party”. RECITALS A. The Company requires an infusion of funds in order to conduct its business activities. B. The Lender is willing to make available the Loan to the Company, on the terms set forth below. NOW, THEREFORE, in consideration of the premises set forth above, the mutual promises and covenants set forth herein and other good and valuable consideration, the parties agree as follows: 1. THE LOAN 1.1 Subject to the terms and conditions hereunder, the Lender agr...",
"BRIDGE LOAN AGREEMENT This BRIDGE LOAN AGREEMENT is made and entered into on October 23, 2020 , by and among the following parties: 1. Cellular Biomedicine Group, Inc., a Delaware corporation ; 2. Yunfeng Capital Limited . The Company and the Lender are collectively referred to below as the “Parties” and each a “Party”. RECITALS A. The Company requires an infusion of funds in order to conduct its business activities. B. The Lender is willing to make available the Loan to the Company, on the terms set forth below. NOW, THEREFORE, in consideration of the premises set forth above, the mutual promises and covenants set forth herein and other good and valuable consideration, the parties agree as follows: 1. THE LOAN 1.1 Subject to the terms and conditions hereunder, ..." |
|
|
|
|